Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma

Tomoko Naito, Shinichi Okuma, Mikio Nagayama, Shiro Mizoue, Mineo Ozaki, Koji Namiguchi, Kazuhisa Miyamoto, Masaki Tanito, Keiji Yoshikawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: We examined the sustainability of the intraocular pressure (IOP)-lowering efficacy of travoprost (0.004%) ophthalmic solution in subjects with normal tension glaucoma (NTG). Methods: Travoprost ophthalmic solution was given once daily at 9 PM to subjects with newly diagnosed NTG or with NTG who had not received any ocular hypotensives within the previous 30 days. IOP was measured at three time points (9 AM, 1 PM, and 5 PM) at baseline and week 12 visits, and at one time point (9 AM) at week 4 and week 8 visits. Conjunctival hyperemia, superficial punctate keratopathy, and other adverse events were evaluated during the observation period. Results: Thirty subjects (12 males and 18 females; mean age 65.6 years) from 32 subjects enrolled were included in the efficacy analysis. The mean IOPs (±standard deviation) of 16.6 ± 1.4, 15.7 ± 1.8, and 15.7 ± 2.2 mmHg at 9 AM, 1 PM, and 5 PM, respectively, at baseline reduced significantly to the mean IOPs of 13.0 ± 1.8, 12.7 ± 1.8, and 12.8 ± 1.6 mmHg, respectively, at week 12 (P <0.0001 for every time point). Together with the mean IOPs of 13.4 ± 1.9 mmHg at week 4 and 13.2 ± 1.9 mmHg at week 8, the pooled IOP during the observation period for up to 12 weeks showed a statistically and clinically significant reduction of IOP at 9 AM. (3.4 mmHg or 20.3% reduction from baseline, P <0.0001). There were no adverse events leading to treatment discontinuation. Conclusion: This multi-center collaborative study suggests that IOP-lowering efficacy of travoprost ophthalmic solution persists during the day at the clinically relevant level in subjects with NTG. Funding: Alcon Japan Ltd. Trial registration: University Hospital Medical Information Network, UMIN ID: 000011621.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalAdvances in Therapy
DOIs
Publication statusAccepted/In press - Feb 9 2016

Fingerprint

Low Tension Glaucoma
Ophthalmic Solutions
Intraocular Pressure
Observation
Information Services
Hyperemia
Japan
Travoprost

Keywords

  • Intraocular pressure (IOP)
  • IOP-lowering
  • Normal tension glaucoma
  • Sustainability
  • Travoprost

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Naito, T., Okuma, S., Nagayama, M., Mizoue, S., Ozaki, M., Namiguchi, K., ... Yoshikawa, K. (Accepted/In press). Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma. Advances in Therapy, 1-12. https://doi.org/10.1007/s12325-016-0297-6

Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma. / Naito, Tomoko; Okuma, Shinichi; Nagayama, Mikio; Mizoue, Shiro; Ozaki, Mineo; Namiguchi, Koji; Miyamoto, Kazuhisa; Tanito, Masaki; Yoshikawa, Keiji.

In: Advances in Therapy, 09.02.2016, p. 1-12.

Research output: Contribution to journalArticle

Naito, T, Okuma, S, Nagayama, M, Mizoue, S, Ozaki, M, Namiguchi, K, Miyamoto, K, Tanito, M & Yoshikawa, K 2016, 'Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma', Advances in Therapy, pp. 1-12. https://doi.org/10.1007/s12325-016-0297-6
Naito, Tomoko ; Okuma, Shinichi ; Nagayama, Mikio ; Mizoue, Shiro ; Ozaki, Mineo ; Namiguchi, Koji ; Miyamoto, Kazuhisa ; Tanito, Masaki ; Yoshikawa, Keiji. / Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma. In: Advances in Therapy. 2016 ; pp. 1-12.
@article{517ee4e659af473ea7edf49c90a226ee,
title = "Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma",
abstract = "Introduction: We examined the sustainability of the intraocular pressure (IOP)-lowering efficacy of travoprost (0.004{\%}) ophthalmic solution in subjects with normal tension glaucoma (NTG). Methods: Travoprost ophthalmic solution was given once daily at 9 PM to subjects with newly diagnosed NTG or with NTG who had not received any ocular hypotensives within the previous 30 days. IOP was measured at three time points (9 AM, 1 PM, and 5 PM) at baseline and week 12 visits, and at one time point (9 AM) at week 4 and week 8 visits. Conjunctival hyperemia, superficial punctate keratopathy, and other adverse events were evaluated during the observation period. Results: Thirty subjects (12 males and 18 females; mean age 65.6 years) from 32 subjects enrolled were included in the efficacy analysis. The mean IOPs (±standard deviation) of 16.6 ± 1.4, 15.7 ± 1.8, and 15.7 ± 2.2 mmHg at 9 AM, 1 PM, and 5 PM, respectively, at baseline reduced significantly to the mean IOPs of 13.0 ± 1.8, 12.7 ± 1.8, and 12.8 ± 1.6 mmHg, respectively, at week 12 (P <0.0001 for every time point). Together with the mean IOPs of 13.4 ± 1.9 mmHg at week 4 and 13.2 ± 1.9 mmHg at week 8, the pooled IOP during the observation period for up to 12 weeks showed a statistically and clinically significant reduction of IOP at 9 AM. (3.4 mmHg or 20.3{\%} reduction from baseline, P <0.0001). There were no adverse events leading to treatment discontinuation. Conclusion: This multi-center collaborative study suggests that IOP-lowering efficacy of travoprost ophthalmic solution persists during the day at the clinically relevant level in subjects with NTG. Funding: Alcon Japan Ltd. Trial registration: University Hospital Medical Information Network, UMIN ID: 000011621.",
keywords = "Intraocular pressure (IOP), IOP-lowering, Normal tension glaucoma, Sustainability, Travoprost",
author = "Tomoko Naito and Shinichi Okuma and Mikio Nagayama and Shiro Mizoue and Mineo Ozaki and Koji Namiguchi and Kazuhisa Miyamoto and Masaki Tanito and Keiji Yoshikawa",
year = "2016",
month = "2",
day = "9",
doi = "10.1007/s12325-016-0297-6",
language = "English",
pages = "1--12",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",

}

TY - JOUR

T1 - Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma

AU - Naito, Tomoko

AU - Okuma, Shinichi

AU - Nagayama, Mikio

AU - Mizoue, Shiro

AU - Ozaki, Mineo

AU - Namiguchi, Koji

AU - Miyamoto, Kazuhisa

AU - Tanito, Masaki

AU - Yoshikawa, Keiji

PY - 2016/2/9

Y1 - 2016/2/9

N2 - Introduction: We examined the sustainability of the intraocular pressure (IOP)-lowering efficacy of travoprost (0.004%) ophthalmic solution in subjects with normal tension glaucoma (NTG). Methods: Travoprost ophthalmic solution was given once daily at 9 PM to subjects with newly diagnosed NTG or with NTG who had not received any ocular hypotensives within the previous 30 days. IOP was measured at three time points (9 AM, 1 PM, and 5 PM) at baseline and week 12 visits, and at one time point (9 AM) at week 4 and week 8 visits. Conjunctival hyperemia, superficial punctate keratopathy, and other adverse events were evaluated during the observation period. Results: Thirty subjects (12 males and 18 females; mean age 65.6 years) from 32 subjects enrolled were included in the efficacy analysis. The mean IOPs (±standard deviation) of 16.6 ± 1.4, 15.7 ± 1.8, and 15.7 ± 2.2 mmHg at 9 AM, 1 PM, and 5 PM, respectively, at baseline reduced significantly to the mean IOPs of 13.0 ± 1.8, 12.7 ± 1.8, and 12.8 ± 1.6 mmHg, respectively, at week 12 (P <0.0001 for every time point). Together with the mean IOPs of 13.4 ± 1.9 mmHg at week 4 and 13.2 ± 1.9 mmHg at week 8, the pooled IOP during the observation period for up to 12 weeks showed a statistically and clinically significant reduction of IOP at 9 AM. (3.4 mmHg or 20.3% reduction from baseline, P <0.0001). There were no adverse events leading to treatment discontinuation. Conclusion: This multi-center collaborative study suggests that IOP-lowering efficacy of travoprost ophthalmic solution persists during the day at the clinically relevant level in subjects with NTG. Funding: Alcon Japan Ltd. Trial registration: University Hospital Medical Information Network, UMIN ID: 000011621.

AB - Introduction: We examined the sustainability of the intraocular pressure (IOP)-lowering efficacy of travoprost (0.004%) ophthalmic solution in subjects with normal tension glaucoma (NTG). Methods: Travoprost ophthalmic solution was given once daily at 9 PM to subjects with newly diagnosed NTG or with NTG who had not received any ocular hypotensives within the previous 30 days. IOP was measured at three time points (9 AM, 1 PM, and 5 PM) at baseline and week 12 visits, and at one time point (9 AM) at week 4 and week 8 visits. Conjunctival hyperemia, superficial punctate keratopathy, and other adverse events were evaluated during the observation period. Results: Thirty subjects (12 males and 18 females; mean age 65.6 years) from 32 subjects enrolled were included in the efficacy analysis. The mean IOPs (±standard deviation) of 16.6 ± 1.4, 15.7 ± 1.8, and 15.7 ± 2.2 mmHg at 9 AM, 1 PM, and 5 PM, respectively, at baseline reduced significantly to the mean IOPs of 13.0 ± 1.8, 12.7 ± 1.8, and 12.8 ± 1.6 mmHg, respectively, at week 12 (P <0.0001 for every time point). Together with the mean IOPs of 13.4 ± 1.9 mmHg at week 4 and 13.2 ± 1.9 mmHg at week 8, the pooled IOP during the observation period for up to 12 weeks showed a statistically and clinically significant reduction of IOP at 9 AM. (3.4 mmHg or 20.3% reduction from baseline, P <0.0001). There were no adverse events leading to treatment discontinuation. Conclusion: This multi-center collaborative study suggests that IOP-lowering efficacy of travoprost ophthalmic solution persists during the day at the clinically relevant level in subjects with NTG. Funding: Alcon Japan Ltd. Trial registration: University Hospital Medical Information Network, UMIN ID: 000011621.

KW - Intraocular pressure (IOP)

KW - IOP-lowering

KW - Normal tension glaucoma

KW - Sustainability

KW - Travoprost

UR - http://www.scopus.com/inward/record.url?scp=84957704076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957704076&partnerID=8YFLogxK

U2 - 10.1007/s12325-016-0297-6

DO - 10.1007/s12325-016-0297-6

M3 - Article

C2 - 26861847

AN - SCOPUS:84957704076

SP - 1

EP - 12

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

ER -